Abstract
The global mpox outbreak has recently been declared a public health emergency of international concern. In this paper, we investigate the spread of mpox primarily evolving and propagating within a core population before affecting the general population. A main public health concern is that through evolution, mpox gains the ability to widely spread in the entire population. We examine how effective various intervention strategies are in preventing this from happening. These non-pharmaceutical inter-ventions include reducing disease transmission in the core population, in the general population, or in both. Our analysis encompasses the optimal timing for these interventions, considering the effects of early versus late intervention and the potential impact of different mutation patterns on disease spread. Our findings highlight that effective early intervention can be achieved with lower intensity, while delayed intervention requires stronger measures. Notably, our results reveal an intriguing phenomenon where moderate intervention could lead to worse outcome than no intervention. This counterintuitive outcome arises because moderate restrictions may prolong transmission chains within the core group, leading to more opportunities for the pathogen to acquire mutations resulting in higher transmission potential in the general population. Consequently, a comprehensive understanding of the role of the core group in disease dynamics and the mutation patterns is crucial for developing tailored and effective public health strategies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors were supported by the National Research, Development and Innovation Office (NKFIH) in Hungary, grants RRF-2.3.1-21-2022-00006, TKP-2021-EGA-05, KKP 129877, 2022-2.1.1-NL-2022-00005. The project has received funding from the EU Horizon 2020 research and innovation program under grant agreement No. 739593.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.
